Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Gains from Investment Securities (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Gains from Investment Securities data on record, last reported at $859873.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 166.14% year-over-year to $859873.0; the TTM value through Dec 2025 reached $859873.0, up 298.13%, while the annual FY2025 figure was $859873.0, 87.21% down from the prior year.
  • Gains from Investment Securities reached $859873.0 in Q4 2025 per ACRS's latest filing, down from $12.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $16.4 million in Q1 2021 and bottomed at -$2.7 million in Q2 2024.
  • Average Gains from Investment Securities over 5 years is $3.1 million, with a median of $2.3 million recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: soared 10299.24% in 2021, then plummeted 11528.57% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $2.2 million in 2021, then increased by 10.64% to $2.4 million in 2022, then fell by 1.31% to $2.4 million in 2023, then tumbled by 154.12% to -$1.3 million in 2024, then skyrocketed by 166.14% to $859873.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $859873.0 in Q4 2025, $12.6 million in Q2 2025, and $275000.0 in Q1 2025.